Loading organizations...
§ Private Profile · Nashville, TN, USA
Healthcare analytics company measuring physician performance for employers and health plans, focused on improving patient outcomes and lowering costs.
Based in Nashville, Tennessee, Embold is a business-to-business healthcare analytics company that measures individual physician performance to provide transparent quality metrics for employers and health plans. The platform evaluates over 545,000 healthcare providers nationwide across 21 specialties using objective clinical data derived from a dataset covering more than 230 million lives. Operating with an estimated 51 to 100 employees, the business currently serves over 5 million members across more than 20 enterprise clients seeking to reduce medical costs. The enterprise secured $23 million in Series B funding backed by institutional investors including Echo Health Ventures, Morgan Health, Chrysalis Ventures, and Whistler Capital Partners. Embold has also partnered with researchers from Harvard Medical School to analyze wide variations in clinical care decisions among thousands of doctors. The organization was officially founded in 2017 by Daniel Stein.
Embold has raised $10.8M across 3 funding rounds.
Embold has raised $10.8M in total across 3 funding rounds.
Embold has raised $10.8M across 3 funding rounds. Most recently, it raised $5.0M Embold Health - Series B in March 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 16, 2022 | $5M Series B | Echo Health Ventures | Chrysalis Ventures, DAN Mendelson, Whistler Capital Partners | Announced |
| Jan 23, 2018 | $2.8M Series A | Capnamic Ventures | — | Announced |
| Jan 1, 2018 | $3M Seed | — | Capnamic Ventures | Announced |
Embold Technologies GmbH (formerly Acellere GmbH) is a software technology company that builds an AI-based static code analysis platform called Embold, designed to automate, analyze, and improve software quality across multiple dimensions.[1][2][4] It serves software development teams worldwide, addressing the high cost of code defects—where over 80% of teams report taking a day or more to fix a single line—by enabling prevention through early detection of issues in code, design, metrics, and duplication, impacting stability, robustness, security, and maintainability.[2][5] The platform supports over 12 languages (e.g., Java, C/C++, C#, Python), integrates with IDEs, version control, and build systems, and deploys via SaaS, hybrid, on-premise, Docker, or Kubernetes; with ~42 employees, $12.7-16M revenue, and $2.8-5M funding, Embold shows steady growth from its R&D roots.[2][4]
Embold originated from a vision a decade ago by Vishal Rai (CEO) and Sudarshan Bhide (CTO) to revolutionize code writing and design, spotting gaps in existing developer tools.[1][2] After 10 years of extensive R&D starting around 2009 (as Acellere), the company launched Embold in 2018 as a static code analysis tool.[1][2] Headquartered in Frankfurt, Germany, with an R&D center in Pune, India, and presence in Japan (Tokyo office/partners), it expanded globally, backed by business angels and VCs, evolving from services to a cutting-edge AI analytics product used by teams worldwide.[1][2][4]
Embold stands out in static code analysis through these key strengths:
Embold rides the DevSecOps and AI-driven developer tools trend, where rising software complexity and mission-critical applications demand proactive quality assurance to cut defect costs and accelerate delivery.[2][5] Timing aligns with Kubernetes/Docker adoption and AI integration in SDLC, as teams shift from reactive fixes to prevention amid growing technical debt from design flaws.[2][5] Market forces like remote/global teams and security mandates favor its multi-language, hybrid deployment; it influences the ecosystem by empowering startups (e.g., space tech like Skyroot) and enterprises to maintain clean, secure code, reducing downstream expenses in a $16M-revenue scaling firm.[1][2][5]
Embold is poised for expansion by deepening AI features for predictive analytics and broader language support, capitalizing on DevOps maturity and AI toolchains amid rising demand for maintainable code in AI/ML-heavy projects.[2][5] Trends like zero-trust security and composable architectures will amplify its role, potentially driving revenue past $20M via enterprise wins and partnerships; its global footprint and VC backing position it to shape how teams prevent technical debt at scale. This evolution from R&D vision to quality gatekeeper underscores Embold's foundational impact on cleaner software worldwide.[1][2]
Embold has raised $10.8M in total across 3 funding rounds.
Embold's investors include Echo Health Ventures, Chrysalis Ventures, Dan Mendelson, Whistler Capital Partners, Capnamic Ventures.